Targeting CDK4 and 6 in Cancer Therapy: Emerging Preclinical Insights Related to Abemaciclib

A Wander, Seth; O’Brien, Neil; M Litchfield, Lacey; O’Dea, Declan; Morato Guimaraes, Claudia; J Slamon, Dennis; Goel, Shom

doi:10.1093/oncolo/oyac138

Public

Targeting CDK4 and 6 in Cancer Therapy: Emerging Preclinical Insights Related to Abemaciclib

Shared by NobleBlocks on Aug 2, 2022 • 12:00 AM UTC

Authors:

Seth A Wander

Neil O’Brien

Lacey M Litchfield

Abstract

Abstract Pharmacologic inhibitors of cyclin-dependent kinases 4 and 6 (CDK4 and 6) are approved for the treatment of subsets of patients with hormone receptor positive (HR+) breast cancer (BC). In metastatic disease, strategies involving endocrine therapy combined with CDK4 and 6 inhibitors (CDK4 an...

Discussions